ASGR1 inhibitors may increase the risk of cholelithiasis through elevating biliary cholesterol excretion [4], similar to adenosine triphosphate-binding cassette transporters G5/8 (ABCG5/8) [7]. This evidence concerns the gene ASGR1 and cholelithiasis.